Related Experiment Videos
The effect of disodium cromoglycate against bronchial hyperresponsiveness in asthmatic children
1Department of Pediatrics, Kawasaki Kyodo Hospital, Japan.
Insights
Long-term use of cromolyn sodium reduced bronchial hyperresponsiveness and improved symptoms in children with asthma. This study highlights its potential for managing pediatric asthma effectively.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Pharmacology
Background:
- Asthma is a chronic respiratory disease characterized by bronchial hyperresponsiveness.
- Effective long-term management strategies for pediatric asthma are crucial.
- Cromolyn sodium is an established mast cell stabilizer with potential anti-inflammatory effects.
Purpose of the Study:
- To evaluate the long-term efficacy of inhaled cromolyn sodium in reducing bronchial hyperresponsiveness in asthmatic children.
- To assess the impact of cromolyn sodium on clinical symptoms of pediatric asthma over a three-year period.
Main Methods:
- A three-year prospective study involving asthmatic children.
- Inhaled cromolyn sodium (20 mg powder via Spinhaler Turbohaler, three times daily).
- Standardized histamine inhalation tests conducted every six months.
- Exclusion of other antiasthmatic therapies except for acute exacerbations.
Main Results:
- Significant reduction in bronchial hyperresponsiveness observed throughout the study.
- Consistent improvement in clinical asthma symptoms reported.
- Cromolyn sodium was well-tolerated over the three-year treatment duration.
Conclusions:
- Long-term administration of inhaled cromolyn sodium effectively reduces bronchial hyperresponsiveness in asthmatic children.
- Cromolyn sodium treatment leads to concomitant improvement in clinical symptomatology.
- Inhaled cromolyn sodium represents a valuable therapeutic option for long-term asthma management in pediatric populations.
Abstract:
A long-term study of the effect of cromolyn sodium against bronchial hyperresponsiveness in asthmatic children is described. Cromolyn sodium powder (20 mg), as the capsule formulation, was inhaled by Spinhaler Turbohaler, tid, for three years. Histamine inhalation tests were performed every 6 months according to the standardized methods of the Japanese Allergy Congress. No other antiasthmatic therapy was given throughout the study except during an acute attack. Bronchial hyperresponsiveness decreased, and clinical symptoms improved throughout the trials. It is suggested that long-term use of cromolyn sodium reduces bronchial hyperresponsiveness concomitant with improved symptomatology in asthmatic children.